Published in J Virol on May 01, 2005
A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region. J Virol (2011) 0.87
Establishment and characterization of plasmid-driven minigenome rescue systems for Nipah virus: RNA polymerase I- and T7-catalyzed generation of functional paramyxoviral RNA. Virology (2007) 0.86
5'-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev (1980) 6.14
Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene. Proc Natl Acad Sci U S A (1991) 4.35
The influenza virus panhandle is involved in the initiation of transcription. J Virol (1994) 3.56
Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE. Methods Enzymol (1993) 3.48
The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A (2003) 3.34
Extent of terminal complementarity modulates the balance between transcription and replication of vesicular stomatitis virus RNA. Proc Natl Acad Sci U S A (1994) 3.13
Promoter elements in the influenza vRNA terminal structure. RNA (1996) 2.97
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
Mutational analysis of influenza virus promoter elements in vivo. J Gen Virol (1995) 2.59
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A (1992) 2.44
Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annu Rev Genet (1998) 2.42
Sequence and genome organization of Borna disease virus. J Virol (1994) 2.41
The remarkable coding strategy of borna disease virus: a new member of the nonsegmented negative strand RNA viruses. Virology (1995) 2.17
Completion of the rabies virus genome sequence determination: highly conserved domains among the L (polymerase) proteins of unsegmented negative-strand RNA viruses. Virology (1988) 2.02
Mutational analysis of the promoter required for influenza virus virion RNA synthesis. J Virol (1992) 2.01
Borna disease virus (BDV), a nonsegmented RNA virus, replicates in the nuclei of infected cells where infectious BDV ribonucleoproteins are present. J Virol (1994) 1.93
Epidemiology of Borna disease virus. J Gen Virol (2000) 1.89
Molecular biology of borna disease virus: prototype of a new group of animal viruses. J Virol (1994) 1.83
Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA. Virology (1991) 1.80
A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? J Gen Virol (2002) 1.60
Regulation of RNA synthesis by the genomic termini of vesicular stomatitis virus: identification of distinct sequences essential for transcription but not replication. J Virol (1999) 1.58
Borna disease virus: a mystery as an emerging zoonotic pathogen. Vet J (2001) 1.57
Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2003) 1.56
RNA splicing in Borna disease virus, a nonsegmented, negative-strand RNA virus. J Virol (1994) 1.50
Virus promoters determine interference by defective RNAs: selective amplification of mini-RNA vectors and rescue from cDNA by a 3' copy-back ambisense rabies virus. J Virol (1999) 1.40
Identification of signal sequences that control transcription of borna disease virus, a nonsegmented, negative-strand RNA virus. J Virol (1994) 1.30
Sequence heterogeneity in the termini of lymphocytic choriomeningitis virus genomic and antigenomic RNAs. J Virol (1994) 1.30
Active borna disease virus polymerase complex requires a distinct nucleoprotein-to-phosphoprotein ratio but no viral X protein. J Virol (2003) 1.27
Initiation of vesicular stomatitis virus mutant polR1 transcription internally at the N gene in vitro. J Virol (1997) 1.27
Borna disease virus and the brain. Brain Res Bull (1997) 1.23
Conservation of coding potential and terminal sequences in four different isolates of Borna disease virus. J Gen Virol (2001) 1.21
Analysis of the 3' terminal sequence recognized by the Rift Valley fever virus transcription complex in its ambisense S segment. Virology (1997) 1.19
The efficiency of Sendai virus genome replication: the importance of the RNA primary sequence independent of terminal complementarity. Virology (1996) 1.19
A reverse genetics system for Borna disease virus. J Gen Virol (2003) 1.16
Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus. J Virol (2000) 1.11
High-avidity human serum antibodies recognizing linear epitopes of Borna disease virus proteins. Biol Psychiatry (2002) 1.08
Borna disease virus infection in animals and humans. Emerg Infect Dis (1997) 1.07
Conserved vRNA end sequences of Thogoto-orthomyxovirus suggest a new panhandle structure. Arch Virol (1997) 1.03
Borna disease. Emerg Infect Dis (1997) 0.98
Accumulation of terminally deleted RNAs may play a role in Seoul virus persistence. J Virol (2000) 0.98
Borna disease virus and human disease. Clin Microbiol Rev (2001) 0.97
Identification of alternative splicing and negative splicing activity of a nonsegmented negative-strand RNA virus, Borna disease virus. Proc Natl Acad Sci U S A (2000) 0.95
A novel type of defective viral genome suggests a unique strategy to establish and maintain persistent lymphocytic choriomeningitis virus infections. J Virol (1997) 0.95
Identification of a novel sequence at the 3' end of the GB virus B genome. J Virol (1999) 0.93
Given the opportunity, the Sendai virus RNA-dependent RNA polymerase could as well enter its template internally. J Virol (2002) 0.90
Identification and characterization of a new intron in Borna disease virus. J Gen Virol (2001) 0.87
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Role of tau protein in both physiological and pathological conditions. Physiol Rev (2004) 2.44
Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J Virol (2002) 1.97
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A (2006) 1.79
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol (2003) 1.69
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A (2013) 1.60
Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol (2004) 1.58
Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan. J Virol (2005) 1.56
Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2003) 1.56
Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A (2011) 1.51
Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol (2002) 1.44
Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A (2003) 1.41
Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest (2004) 1.39
Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol (2005) 1.36
Arenavirus Z-glycoprotein association requires Z myristoylation but not functional RING or late domains. J Virol (2007) 1.27
The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology (2011) 1.22
A reverse genetics system for Borna disease virus. J Gen Virol (2003) 1.16
Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε. J Virol (2012) 1.15
Cellular entry of lymphocytic choriomeningitis virus. J Virol (2007) 1.12
Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses (2010) 1.11
The z protein of the new world arenavirus tacaribe virus has bona fide budding activity that does not depend on known late domain motifs. J Virol (2009) 1.10
Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J Virol (2007) 1.09
Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol (2010) 1.06
Junín virus infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl Trop Dis (2012) 1.05
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling. Mol Immunol (2008) 0.99
GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus (2010) 0.99
Cells expressing the RING finger Z protein are resistant to arenavirus infection. J Virol (2004) 0.98
RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2005) 0.97
A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology (2008) 0.97
Altered central nervous system gene expression caused by congenitally acquired persistent infection with lymphocytic choriomeningitis virus. J Virol (2006) 0.96
Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific manner. Cell Host Microbe (2011) 0.93
Role of the host cell's unfolded protein response in arenavirus infection. J Virol (2010) 0.93
Identification of the Borna disease virus (BDV) proteins required for the formation of BDV-like particles. J Gen Virol (2005) 0.91
Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog (2006) 0.91
A methionine-rich domain mediates CRM1-dependent nuclear export activity of Borna disease virus phosphoprotein. J Virol (2006) 0.89
Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology (2011) 0.89
Conserved residues in Lassa fever virus Z protein modulate viral infectivity at the level of the ribonucleoprotein. J Virol (2011) 0.88
Borna disease virus requires cholesterol in both cellular membrane and viral envelope for efficient cell entry. J Virol (2009) 0.87
The PI3K/Akt pathway contributes to arenavirus budding. J Virol (2012) 0.87
Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis (2009) 0.87
Arenavirus budding. Adv Virol (2011) 0.87
Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system. J Gen Virol (2008) 0.85
1-beta-D-arabinofuranosylcytosine inhibits borna disease virus replication and spread. J Virol (2002) 0.84
Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells. J Vis Exp (2013) 0.82
Borna disease virus RNA detected in Japanese macaques (Macaca fuscata). Primates (2007) 0.82
Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J Virol (2013) 0.81
Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One (2012) 0.80
Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid. Antiviral Res (2013) 0.77
Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology (2012) 0.77
Retracted gamma-cleavage-independent functions of presenilin, nicastrin, and Aph-1 regulate cell-junction organization and prevent tau toxicity in vivo. Neuron (2006) 0.76
Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid. bioRxiv (2020) 0.75